A new cooling pad enters the healthcare market, joining a growing number of cooling systems used to induce hypothermia ...
November 2006 - Physicians at UT Southwestern Medical Center are part of a multinational clinical trial evaluating the Optimizer System, a unique implantable device designed to treat a larger number of patients with heart failure. UT Southwestern is one of the top enrolling centers of the 50 sites in the U.S.
Healthcare IT companies will again converge this winter to measure their ability to integrate with each other during the ...
Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...
While general endotracheal anesthesia (GETA) is the most common type of anesthesia used in infrainguinal bypasses, a study published in the November issue of the Journal of Vascular Surgery reveals that it may not be the best strategy.
Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...
A large California-based study has shown that patients with heart failure who start taking statins, compared with those who don't, will live longer and have a lower hospitalization risk regardless of cholesterol levels, presence or absence of coronary disease, and other CV drug therapies, “Heartwire” reported this week.
Accurate reporting is essential to producing the reliable analytics needed to meet lab accreditation standards. This is ...
The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...
Agfa HealthCare has signed a multi-million dollar deal with Thomas Memorial Hospital in South Charleston, WV and will ...
British researchers have concluded that counseling and education aimed at preventing coronary heart disease have no impact on mortality and little effect in terms of clinical events, reports “heartwire.” Dr Shah Ebrahim (London School of Tropical Medicine, UK) and colleagues report their findings in the Oct. 18, 2006 Cochrane Database of Systematic Reviews.
Jeff Rieder M.D., a cardiologist with Coastal Cardiology Charleston, clearly recalls the time when reporting was ...
A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System ...
TeraRecon Inc. and Commissure, Inc. have announced a partnership to integrate and deliver seamless workflow ...
The FDA has granted approval to Cook Inc. for its new 36mm Zenith FLEX AAA Endovascular Graft for the treatment of ...
During the COVID-19 pandemic, many cardiology departments were faced with the daunting task of supporting inpatient and ...
Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.
Cardium Therapeutics and its subsidiary InnerCool Therapies reported on preclinical data demonstrating a new and ...
A stent designed to dissolve after it completes its task of propping open narrowed heart arteries is being tested by scientists. The first human experiment with the dissolving stent is being conducted with 26 patients at hospitals in New Zealand and Europe, the Associated Press reported. The study is designed to test whether the stent is safe enough to be used in larger studies.